Neurocrine Biosciences Inc (NAS:NBIX)
$ 136.53 -0.46 (-0.34%) Market Cap: 13.82 Bil Enterprise Value: 12.85 Bil PE Ratio: 36.60 PB Ratio: 5.08 GF Score: 88/100

Neurocrine Biosciences Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 05:00PM GMT
Release Date Price: $78.81 (+3.38%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Good morning. Thanks for joining us at the Bank of America Merrill Lynch Conference. I am Tazeen Ahmad. I'm the senior SMid biotech analyst here. It's my pleasure to introduce our next presenting company. Sitting next to me are 2 of the members of the management team from Neurocrine: Kevin Gorman, who is the Chief Executive Officer; as well as Matt Abernethy, who's Chief Financial Officer.

The format is going to be Q&A. So feel free to raise your hand if you have any questions from the audience. But maybe Kevin, for those few people who don't know that much about Neurocrine, maybe for 2 minutes, you can tell us about the company and where you're at, and we can go from there.

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

Sure. Thank you, Tazeen, and thank you, Bank of America, for the invitation to speak here today. I don't have a slide for it, but we will be making forward-looking statements. So I'd like to direct you to our recent SEC filings for all the cautions and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot